Cabozantinib,Atezolizumab
Exelixis,roche
['prostate', 'exelixis', 'exelixisinc']
contact-02 is actively enrolling eligible patients with metastatic prostate cancer. visit us at #asco22 booth 18063 or online to learn more.
Biotechnology company striving to accelerate the development of new medicines for difficult-to-treat cancers. See our guidelines: https://t.co/eaLlId7wLk